Table 2.
Efficacy of salvage therapy in 34 patients
| ORR | DCR | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|||||||||||
| Cases | PR | SD | PD | % | χ2 | P | % | χ2 | P | ||
| Gender | Men | 23 | 3 | 8 | 12 | 13.0 | 0.112 | 0.738 | 47.8 | 0.134 | 0.714 |
| Women | 11 | 1 | 5 | 5 | 9.1 | 54.5 | |||||
| PS score | 0-1 | 22 | 3 | 10 | 9 | 13.6 | 0.210 | 0.647 | 59.1 | 2.061 | 0.151 |
| ≥2 | 12 | 1 | 3 | 8 | 8.3 | 33.3 | |||||
| TKI time, months | ≥6 | 12 | 3 | 6 | 3 | 25.0 | 1.469 | 0.226 | 75.0 | 4.636 | 0.031 |
| <6 | 22 | 1 | 7 | 14 | 4.5 | 36.4 | |||||
| Regimen | A | 20 | 2 | 9 | 9 | 10.0 | 0.146 | 0.703 | 55.0 | 1.630 | 0.728 |
| B | 14 | 2 | 4 | 8 | 14.3 | 42.9 | |||||
Note: No., number of patients. EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor. PR: Partial response, SD: stable disease, PD: progressive disease, CR: complete response, ORR: objective response rate, DCR: disease control rate.